bictegravir and lofexidine

bictegravir has been researched along with lofexidine* in 2 studies

Other Studies

2 other study(ies) available for bictegravir and lofexidine

ArticleYear
New Drugs 2019, part 2.
    Nursing, 2019, Volume: 49, Issue:5

    This article reviews eight drugs recently approved by the FDA, including indications, precautions, adverse reactions, and nursing considerations.

    Topics: Amides; Angiotensin II; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Azetidines; Clonidine; Drug Approval; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; Humans; Hydrocarbons, Fluorinated; Piperazines; Purines; Pyrazoles; Pyridones; Pyrimidines; Silicates; Sulfonamides; United States; United States Food and Drug Administration

2019
Drug updates and approvals: 2018 in review.
    The Nurse practitioner, 2018, Volume: 43, Issue:12

    In 2018, the FDA approved several new drugs for use in primary care. This article highlights the following new drugs: bictegravir, emtricitabine, and tenofovir alafenamide (Biktarvy); doxylamine succinate and pyridoxine hydrochloride (Bonjesta); erenumab-aooe (Aimovig); lofexidine hydrochloride (Lucemyra); tezacaftor and ivacaftor (Symdeko); and tildrakizumab-asmn (Ilumya).

    Topics: Adenine; Alanine; Amides; Aminophenols; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzodioxoles; Clonidine; Doxylamine; Drug Approval; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; Humans; Indoles; Piperazines; Pyridones; Pyridoxine; Quinolones; Tenofovir; United States; United States Food and Drug Administration

2018